Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Jay C. Buckey Jr.
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07240649CT.gov Outcomes From Hyperbaric Oxygen (HBO2) Treatment for Emerging Indications | — | Not Yet Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Ulcer Of Lower Limbs
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Oxygen (this asset) | Jay C. Buckey Jr. | Approved | BB · 64 |
| Sevoflurane | Charles University, Czech Republic | P4 | BB |
| Cyteal | Charles University, Czech Republic | P4 | BB |
| Peripheral Blood Mononuclear Cell | Mahidol University | P3 | BB |
| Allogeneic Adipose-Derived Mesenchymal Stem Cells | Medical University of Warsaw | P2 | B |
| Pegylated Carboxyhemoglobin Bovine | Prolong Pharmaceuticals | P2 | B |
| Uniprost | United Therapeutics | P3 | B |
| Voxelotor | Pfizer | P3 | CCC |
| Dermaseal | Vitruvian Medical Devices, Inc. | P1 | NR |
+1 more in the Ulcer Of Lower Limbs cohort
Other indications for Oxygen
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Anxiety Disorder | — | P4 | BB · 66 |
| Benign Prostatic Hyperplasia | — | P4 | BB · 66 |
| Prostate Disorder | — | P4 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Oxygen in Ulcer Of Lower Limbs. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/oxygen-ulcer-of-lower-limbs
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →